June 15, 2017
Patients does in LEO Pharma’s atopic dermatitis study
LEO Pharma has dosed patients in a phase 3 clinical study of its investigational human monoclonal antibody tralokinumab.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: tralokinumab